Featured Research

from universities, journals, and other organizations

Use Of Ghostwriters, Guest Authors Appears Frequent For Studies Involving Rofecoxib

Date:
April 15, 2008
Source:
JAMA and Archives Journals
Summary:
An examination of medical articles about rofecoxib and court documents from litigation related to this product indicates that company employees or other unacknowledged authors were frequently involved in writing clinical trial articles and review articles, but that primary authorship was often attributed to academically affiliated investigators who may have had little to do with the study, or who did not always disclose financial support from the sponsor of the study, according to a new article.

An examination of medical articles about rofecoxib (a nonsteroidal anti-inflammatory drug) and court documents from litigation related to this product indicates that company employees or other unacknowledged authors were frequently involved in writing clinical trial articles and review articles, but that primary authorship was often attributed to academically affiliated investigators who may have had little to do with the study, or who did not always disclose financial support from the sponsor of the study, according to an article in the April 16 issue of JAMA.

Related Articles


Authorship in biomedical publication provides recognition while establishing accountability and responsibility. Guest authorship has been defined as the designation of an individual who does not meet authorship criteria, according to background information in the article. Ghostwriting has been defined as the failure to designate an individual (as an author) who has made a substantial contribution to the research or writing of a manuscript.

"Recent litigation related to rofecoxib provided a unique opportunity to examine guest authorship and ghostwriting, practices that have been suspected in biomedical publication but for which there is little documentation," the authors write.

Joseph S. Ross, M.D., M.H.S., of Mount Sinai School of Medicine, New York, and colleagues conducted a case-study review of court documents, in combination with a review of the relevant medical literature, to describe the practice of guest authorship and ghostwriting related to rofecoxib. The researchers used court documents, created predominantly between 1996 and 2004, originally obtained during litigation related to rofecoxib against Merck & Co. Inc. In addition, publicly available articles related to rofecoxib were identified via MEDLINE. Approximately 250 documents were relevant for the review.

When publishing their own clinical trials (designed, conducted, and sponsored by Merck), documents were found describing Merck scientists often working to prepare manuscripts and subsequently recruiting external, academically affiliated investigators to collaborate on the manuscript as guest authors. "Recruited authors were frequently placed in the first and second positions of the authorship list. For the publication of scientific review papers, documents were found describing Merck marketing employees developing plans for manuscripts, contracting with medical publishing companies to ghostwrite manuscripts, and recruiting external, academically affiliated investigators to be authors," the researchers write. Documents indicated that medical publishing companies provided near complete drafts of review manuscripts to authors for editing, in addition to managing submissions and revisions.

Documents were also found describing Merck compensating investigators with honorarium for agreeing to serve as authors on review manuscripts ghostwritten on their behalf by medical publishing companies. "Among 96 relevant published articles, we found that 92 percent (22 of 24) of clinical trial articles published a disclosure of Merck's financial support, but only 50 percent (36 of 72) of review articles published either a disclosure of Merck sponsorship or a disclosure of whether the author had received any financial compensation from the company."

"This case-study review of industry documents related to rofecoxib demonstrates that Merck used a systematic strategy to facilitate the publication of guest authored and ghost written medical literature," the authors write. "We are hopeful that our findings encourage discussion of ways in which to improve the integrity of research. The medical profession and the pharmaceutical industry should agree that collaborations must be conducted with the highest standards. We suggest that academic researchers consistently provide to the journals the author contributions for all manuscripts, including original research, meta-analyses, reviews, and commentaries, and disclose relationships and support from all industry sources, regardless of the journal's requirements."

"Authors who 'sign-off' on or 'edit' original manuscripts or reviews written explicitly by pharmaceutical industry employees or by medical publishing companies should offer full authorship disclosure, such as, 'drafting of the manuscript was done by representatives from XYZ, Inc.; the authors were responsible for critical revisions of the manuscript for important intellectual content.' A coordinated oversight strategy involving academic physicians, journal editors, and industry representatives is necessary to discourage both guest authorship and ghostwriting and improve the integrity of the biomedical authorship system," the authors conclude.

Journal reference: JAMA. 2008;299[15]:1800-1812.

Disclosure: All of the authors have been compensated for their work as consultants at the request of plaintiffs in litigation against Merck & Co. Inc. related to rofecoxib. Co-author Dr. Krumholz reported serving on the advisory boards of Amgen and UnitedHealthcare and being a subject expert for VHA Inc.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Cite This Page:

JAMA and Archives Journals. "Use Of Ghostwriters, Guest Authors Appears Frequent For Studies Involving Rofecoxib." ScienceDaily. ScienceDaily, 15 April 2008. <www.sciencedaily.com/releases/2008/04/080415164323.htm>.
JAMA and Archives Journals. (2008, April 15). Use Of Ghostwriters, Guest Authors Appears Frequent For Studies Involving Rofecoxib. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2008/04/080415164323.htm
JAMA and Archives Journals. "Use Of Ghostwriters, Guest Authors Appears Frequent For Studies Involving Rofecoxib." ScienceDaily. www.sciencedaily.com/releases/2008/04/080415164323.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Fauci Says Ebola Risk in US "essentially Zero"

Fauci Says Ebola Risk in US "essentially Zero"

AP (Oct. 30, 2014) NIAID Director Anthony Fauci said the risk of Ebola becoming an epidemic in the U.S. is essentially zero Thursday at the Washington Ideas Forum. He also said an Ebola vaccine will be tested in West Africa in the next few months. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Nurse Defies Ebola Quarantine With Bike Ride

Nurse Defies Ebola Quarantine With Bike Ride

AP (Oct. 30, 2014) A nurse who vowed to defy Maine's voluntary quarantine for health care workers who treated Ebola patients followed through on her promise Thursday, leaving her home for an hour-long bike ride. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Pot-Infused Edibles Raise Concerns in Colorado

Pot-Infused Edibles Raise Concerns in Colorado

AFP (Oct. 30, 2014) Colorado may have legalized marijuana for recreational use, but the debate around the decision still continues, with a recent - failed - attempt to ban cannabis-infused edibles. Duration: 01:53 Video provided by AFP
Powered by NewsLook.com
British Navy Ship Arrives in Sierra Leone With Ebola Aid

British Navy Ship Arrives in Sierra Leone With Ebola Aid

AFP (Oct. 30, 2014) The British ship RFA ARGUS arrived in Sierra Leone to deliver supplies and equipment to help the fight against Ebola. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins